DelveInsight’s, “Thalassemia Pipeline Insight, 2023” report provides comprehensive insights about 30+ Thalassemia companies and 30+ pipeline drugs in Thalassemia pipeline landscape. It covers the Thalassemia pipeline drug profiles, including Thalassemia clinical trials and nonclinical stage products. Thalassemia pipeline report also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
In the Thalassemia Pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Thalassemia clinical trials studies, Thalassemia NDA approvals (if any), and product development activities comprising the technology, Thalassemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Thalassemia Pipeline Report
To explore more information on the latest breakthroughs in the Thalassemia Pipeline treatment landscape of the report, click here @ Thalassemia Pipeline Outlook
Thalassemia Overview
Thalassemia is a blood disorder that is inherited. This means it is passed down from one or both parents through their genes. When a person has thalassemia, the body makes less hemoglobin than normal. Hemoglobin is an iron-rich protein in red blood cells. It carries oxygen to all parts of the body. There are 2 main types of thalassemia: alpha and beta. Different genes are affected for each type. Thalassemia can cause mild or severe anemia. Anemia occurs when the body does not have enough red blood cells or hemoglobin. The severity and type of anemia depends on how many genes are affected. Alpha thalassemia occurs when some or all of the 4 genes that make hemoglobin (the alpha-globin genes) are missing or damaged. There are 4 types of alpha thalassemia: Alpha thalassemia silent carrier: One gene is missing or damaged, and the other 3 are normal. Alpha thalassemia carrier: Two genes are missing.
Latest Developmental Activities in the Thalassemia Treatment Landscape
For further information, refer to the detailed Thalassemia Unmet Needs, Thalassemia Market Drivers, and Thalassemia Market Barriers, click here for Thalassemia Ongoing Clinical Trial Analysis
Thalassemia Emerging Drugs Profile
CTX-001: CRISPR Therapeutics
CTX001 is an autologous CRISPR/Cas9 gene-edited hematopoietic stem cell therapy in development for patients suffering from β-thalassemia and sickle cell disease. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Beta-Thalassemia.
Mitapivat: Agios Pharmaceuticals
Mitapivat is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase R (PKR) enzymes. Currently, the drug is in Phase III stage of Clinical trial evaluation for the treatment of Transfusion-dependent Alpha or Beta Thalassemia.
DST-0509: DisperSol Technologies
DST-0509, is an investigational drug being developed by DisperSol Technologies. It belongs, to the class of antianaemics.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Thalassemia.
Thalassemia Pipeline Therapeutics Assessment
There are approx. 30+ key Thalassemia companies which are developing the therapies for Thalassemia. The companies which have their Thalassemia drug candidates in the most advanced stage, i.e. phase III include, CRISPR Therapeutics.
Request a sample and discover the recent advances in Thalassemia Ongoing Clinical Trial Analysis and Medications, click here @ Thalassemia Treatment Landscape
Scope of the Thalassemia Pipeline Report
Dive deep into rich insights for drugs for Thalassemia Market Drivers and Thalassemia Market Barriers, click here @ Thalassemia Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Thalassemia Mergers and acquisitions, Thalassemia Licensing Activities @ Thalassemia Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/